ZENTALIS PHARMACEUTICALS INC. - COMMON STOCK

Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference

09 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2022

08 Mar 2022 16:30:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

24 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

03 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021

02 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma

17 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present at Two Upcoming Investor Conferences

09 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabine in Patients with Osteosarcoma

13 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2021

09 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

02 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3

01 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update

12 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Virtual Conference

04 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma

02 Aug 2021 07:30:00 By Nasdaq GlobeNewswire

Zentera Therapeutics Announces Closing of $75 Million Series B Financing

02 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

01 Jul 2021 16:01:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock

28 Jun 2021 21:08:56 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock

28 Jun 2021 16:18:03 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, with the First Trial Already Initiated

28 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in the Jefferies Virtual Healthcare Conference

28 May 2021 07:00:00 By Nasdaq GlobeNewswire